What is the utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines?
A study by Yeboah et al. (2016) evaluated the utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. The study included 7,852 individuals with atherosclerotic cardiovascular disease who were ineligible for statin therapy. The participants were evaluated for nontraditional risk markers such as C-reactive protein, coronary artery calcium, and ankle-brachial index. The results showed that there was an association between the risk markers and the risk of cardiovascular events. The results indicated that incorporation of these nontraditional risk markers into the risk assessment of individuals ineligible for statin therapy could provide additional information to guide clinical decision-making.